Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2010

Discovery of a Novel CCR5 Antagonist as an Effective Therapeutic
Agent for Prostate Cancer
Tasrif Ahmed
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Physiology Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/2215

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

Discovery of a Novel CCR5 Antagonist as an Effective Therapeutic Agent for Prostate
Cancer
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.

by

Tasrif Ahmed
B.S. in Biochemistry at University of North Carolina at Chapel Hill, 2008

Director: Zendra Zehner, Ph.D.
Professor, Department of Biochemistry

Virginia Commonwealth University
Richmond, Virginia
July, 2010

i

COPYRIGHT



Tasrif Ahmed
2010
All Rights Reserved

ii

ACKNOWLEDGMENTS

I would like to thank my advisor Dr. Zendra Zehner for giving me the opportunity to
work in her lab and guiding me through every step of my research. I also appreciate all the help
from Dr. Xueping Zhang. She and Dr. Zehner have been very patient with me and allowed me to
work independently. I cannot thank Ms. Amanda Richardson enough for giving me the
introduction to the cell culturing methods and proliferation assays. Dr. Joy Ware has been a vital
part of my research because of her work with M12 cell line and mice. I would also like to thank
Dr. Yan Zhang without whom we would not have this project. He is the person who designed all
the drugs that I tested for my thesis. I also want to acknowledge my fiancée Nur Sultana and my
parents for supporting me in everything I do. They have been very understanding and
motivational.

iii

TABLE OF CONTENTS

Acknowledgements ........................................................................................................................... iii
List of Tables ....................................................................................................................................vi
List of Figures ................................................................................................................................... vii
List of Abbreviations ........................................................................................................................viii
Abstract .............................................................................................................................................x
Background .......................................................................................................................................1
Prostate Cancer .....................................................................................................................1
Classification of Prostate Cancer and other Prostate Abnormalities ....................................2
Diagnosis of Prostate Cancer ................................................................................................3
Treatments for Prostate Cancer .............................................................................................4
The Role of Chronic Inflammation in Prostate Cancer ........................................................4
The Role of CCR5 and CCL5 in Prostate Cancer .................................................................5
The Role of Chemokines in Prostate Cancer ........................................................................6
The Tumor Microenvironment .............................................................................................6
Chemokines and Chemokine Receptors ................................................................................9
Role of MMP in Metastasis of Prostate Cancer ....................................................................10
CCL5 Function ......................................................................................................................11
CCR5 Structure and Signaling Pathway ...............................................................................11
Prostate Cancer Cell Lines ....................................................................................................17
Anti-Prostate Cancer Drug Design .......................................................................................21
Thesis Objectives ..............................................................................................................................23
Materials and Methods ......................................................................................................................25
Cell Media ............................................................................................................................25
2D Cell Culture .....................................................................................................................25
Cell Counting .........................................................................................................................26
Cell Proliferation Assay .........................................................................................................26
Cytotoxicity Assay ................................................................................................................27
Invasion Assay .......................................................................................................................28

iv

Mathematical Analysis and Statistical Calculation................................................................29
Results ...............................................................................................................................................30
The Effect of the First Set of Drugs on Cell Proliferation .....................................................30
The Effect of the Second Set of Drugs on Cell Proliferation ...............................................33
The Effect of the Third Set of 28 Drugs on Cell Proliferation ..............................................40
The Effect of the First Set of 24 Drugs on Cytotoxicity .......................................................40
The Effect of Drug 17 on Cell Proliferation ........................................................................50
The Effect of Drug 17 on the Cytotoxicity Assay of PCa Cells ............................................50
The Effect of Drug 17 on in vitro Invasion of PCa Cells .....................................................57
The Effect of Drug 17 on in vivo Tumor Growth ..................................................................60
Discussion .........................................................................................................................................68
Conclusion ........................................................................................................................................73
List of References .............................................................................................................................74
Vita ....................................................................................................................................................78

v

LIST OF TABLES

1. List of the 76 Drugs that were Tested in in vitro Assays .............................................................24
2. Inhibitory Data for Drugs 17 and 22 ............................................................................................38
3. Tumor Volume and Percent Inhibition of Tumor Size by Drug 17 ..............................................65

vi

LIST OF FIGURES

1. Inflammation in Cancer ................................................................................................................7
2. The Two Dimensional Structure of CCR5 with Palmitolyation Sites and Two Disulfide Bonds .12
3. The CCR5 and CCL5 Pathway in Macrophages ...........................................................................15
4. The M12 Cell Line Expresses More CCL5 mRNA than Parental P69..........................................19
5. The First Set of Drugs Showed No Inhibitory Effect on Growth of M12 Cells ............................31
6. A Repeated Proliferation Assay Showed No Inhibitory Effect for the First Set of Drugs ............34
7. Drug 17 and Drug 22 Inhibited Proliferation of DU145 and PC3 Cells........................................36
8. A Few Drugs of the Third Set of Drugs Moderately Inhibited M12 Cell Proliferation ................41
9. Selected Third Set of Drugs Showed No Inhibition of M12, DU145 or PC-3 Cell Proliferation .43
10. The Cytotoxicity Assay of the First Set of 24 Drugs on M12 Cells ............................................46
11. Drug 17 Caused the Highest Inhibition of DU145 and PC-3 Cells via the Cytotoxicity Assay..48
12. Drug 17 Inhibited Proliferation of DU145, PC3 and M12 Cells at 10µM ..................................51
13. Drug 17 Significantly Inhibited M12 Proliferation at 1uM .........................................................53
14. Calculation of the IC50 for Drug 17 Inhibition of M12 Cell Proliferation. ................................55
15. Drug 17 Significantly Inhibited Growth in a Cytotoxicity Assay ...............................................58
16. Drug 17 Significantly Reduced the Invasiveness of DU145, PC3 and M12 Cells. .....................61
17. Drug 17 Reduced Tumor Growth in vivo. ...................................................................................63

vii

List of Abbreviations
%
°C
µM
Å
AAH
AP-1
AR
BPH
CCL5
CCR5
CDCl3
CI
CO2
COX-2
CXCL12
CXCL16
CXCL8
CXCR4
DAG
DC
DHT
DMF
DMSO
DU-145
ECM
EGF
EGFr
EGF-R
EL2
EP
FBS
FGF-R
g
G-CSF
GOLD
GPCR
HIV
HPV
Ic50
IFN
IGF

percent
degrees Celsius
micromolar
Angstroms
atypical adenomatous hyperplasia
activatory protein 1
androgen receptor
benign prostatic hyperplasia
CC chemokine ligand 5
CC chemokine receptor 5
deuterated chloroform
chronic inflammation
carbon dioxide
cycloxygenase enzyme 2
CXC chemokine ligand 12
CXC chemokine ligand 16
CXC chemokine ligand 8
CXC chemokine receptor 4
Diacylglycerol
dendritic cells
dihydroxytestosterone
dimethylformamide
dimethylsulfoxide
dura mater derived prostate cancer cell line
extracellular matrix
epidermal growth factor
epidermal growth factor receptor
epidermal growth factor receptor
extracellular loop 2
endorcrine-paracrine cell
fetal bovine serum
fibroblast growth factor receptor
grams
granulocyte-colony stimulating factor
genetic optimization for ligand binding
G protein coupled receptor
human immunodeficiency disorder
human papillomavirus
half maximal inhibitory concentration
interferon
insulin-like growth factor
viii

IGFB
IGF-I
IGFR
IGFR
IL
IP3
IR
ITS
JNK
kDa
LC50
LNCaP
m
M12
MeOH
MIF
MIP
mL
mmol
MMP
mRNA
NAD:
NADH
nm
nM
NMR
p53
P69
PBS
PC-3
PCA
PIA
PIN
PIP2
PKC
PLC
PSA
PYK2
TGF
TNF
VEGF

insulin-like growth factor binding protein
insulin-like growth factor type 1
insulin-like growth factor receptor
insulin-like growth factor receptor
interleukin
inositol-1,4,5-triphosphate
infrared
insulin, transferrin, selenium
c-Jun N-terminal kinase
kilodalton
half maximal lethal concentration
lymph node derived prostate cancer cell line
multiplet
metastatic prostate cancer cell line
methanol
mitosis initiation factor
mitosis initiation factor
milliliters
millimolar
matrix metalloproteinase
messenger ribonucleotidic acid
oxidized nicotinamide adenine dinucleotide
reduced nicotinamide adenine dinucleotide
nanometers
nanomolar
nuclear magnetic resonance
tumor protein 53
non-neoplastic prostate epithelial cell line P
phosphate buffer solution
bone derived prostate cancer cell line
prostate cancer
proliferative inflammatory atrophy
prostate intraepithelial neoplasia
phosphatidylinositol-4,5-bisphosphate
Protein Kinase C
phospholipase C
prostatic specific antigen
protein tyrosine kinase 2
transforming growth factor
tumor necrosis factor
vascular endothelial growth factor

ix

Abstract

DISCOVERY OF A NOVEL CCR5 ANTAGONIST AS AN EFFECTIVE THERAPEUTIC
AGENT FOR PROSTATE CANCER

By Tasrif Ahmed

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.

Virginia Commonwealth University, 2010

Major Director: Zendra Zehner, Professor, Department of Biochemistry

Previously, the CCR5 receptor was found to be a good target for treating prostate cancer
(PCa). Dr. Yan Zhang’s laboratory designed several CCR5 antagonists, which were screened for
their inhibitory effect on the growth and invasion of the M12, DU145 and PC-3 PCa cell lines.
Primary in vitro screening showed one compound (Drug 17) significantly inhibited the
proliferation of PCa cells at 1µM concentration, with a half-maximal inhibitory concentration of
237.68 nM. Further in vitro assays including a proliferation, cytotoxicity and invasion assay
confirmed the inhibitory effect of drug 17. The physiological effect of drug 17 was tested by the
Ware laboratory in vivo by subcutaneous injection of M12 cells into male, athymic nude mice.
Tumor growth was slowed in mice receiving injections of drug 17 compared to sham injected
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controls. Thus, in vitro and in vivo assays suggest drug 17 might be an effective therapy to block
PCa progression.

xi

I. Background

Prostate Cancer
Prostate cancer (PCa) originates in the prostate gland, which is an accessory male
reproductive organ. The prostate gland surrounds the urethra that carries urine and semen and
secretes its products into the urethra. A few symptoms of PCa are urinary hesitancy, urinary
retention, pain with urination, pain with ejaculation, and pain with bowel movement [1].
According to the American Cancer Society’s Cancer Statistics for the year 2009, PCa will be
the most diagnosed cancer in males. It is also the second most lethal cancer in men after lung
cancer [2]. Since 1991, many major chronic disease rates have decreased substantially but the
rate of death from cancer only decreased by 16%, although this rate varies among various
ethnic groups and genders [2]. The cancer death rate is higher in men than women in every
ethnic group. African Americans exhibit the highest cancer death rate whereas Asian
American and Pacific Islanders have the lowest [3]. Several therapies are available for
prostate cancer, but they are only beneficial at the early stage, with no significant effect after
metastasis [4]. PCa can metastasize to several sites, but bone metastasis is fatal [5]. In the
past, chronic inflammation has been linked to many types of cancers, but recent investigation
showed that there is also a relationship between prostate cancer and inflammation.
Significant up-regulation of various inflammatory chemokines and receptors in prostate
cancer compared to benign prostatic hyperplasia (BPH) has been noted.

1

Classification of Prostate Cancer and Other Prostate Abnormalities
PCa is classified as a slow progressing adenocarcinoma (cancer of the glandular tissue).
The glands of the prostate produce about 25-30% of the semen volume consisting of acid
phosphatase, citric acid, fibrinolysin, prostate specific antigen (PSA), proteolytic enzymes, and
zinc. This makes the semen slightly alkaline to neutralize the acidity from the vaginal tract and
therefore, increase the sperm lifespan [6]. The prostate consists of glandular tissue and
mesenchymal stroma. It has tubulo-acinar glands that open into the prostatic urethra. The glands
are divided into zones: central, transitional and peripheral. The peripheral zone makes up 70% of
the prostate where PCa is thought to originate [7]. The prostate epithelium consists of three
different types of cells: secretory luminal, basal, and endocrine paracrine (EP) cells. Secretory
luminal cells are the major phenotype in normal prostate epithelium and are highly proliferative.
Their differentiation and development is controlled by the stroma through androgen secretion.
Secretory cells express the androgen receptor (AR) and require a continuous supply of androgens
for growth; however, basal cells are androgen-independent. The stroma and the luminal
epithelium cells act in a paracrine fashion to support the development and differentiation of each
other by releasing various factors [8].

The AR expression level is higher during prostate

hypertrophy compared to the normal prostate. For this reason, androgen suppression is a widely
used first line of defense against prostate cancer. However, this may lead to the selection of
androgen-independent cancer cells [9].
There are several different pathways by which cells can become androgen independent,
such as the hypersensitivity, promiscuous, outlaw, bypass or lurker cell pathway [9]. In the
hypersensitivity pathway the AR expression is up-regulated or AR is more sensitive for the
ligand to compensate for the low levels of androgen. In the promiscuous pathway, the AR loses
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its specificity and binds other molecules. In the outlaw pathway, receptor tyrosine kinases are
activated so the AR is activated through phosphorylation by protein kinase B (AKT) or mitogenactivated protein kinase (MAPK) such that androgen binding is obviated. In the bypass pathway,
other parallel survival pathways are activated, which involve anti-apoptotic proteins that no
longer require the AR pathway. Lastly, in the lurker cell pathway androgen independent cells
are selected for by androgen depression therapy [9].
Beside PCa, several other types of abnormalities occur in different zones of the prostate
gland such as BPH, atypical adenomatous hyperplasia (AAH), proliferative inflammatory
atrophy (PIA) and prostate intraepithelial neoplasia (PIN). BPH and AAH occur in the
transitional zone while PIA and PIN occur in the peripheral zone [10]. BPH is very common in
men as they age and usually is non-symptomatic and non-cancerous [11,12]. What causes the
prostate cells to become cancerous is unknown, but the role of chronic inflammation is evident
from previous studies.
Diagnosis of Prostate Cancer
The median age of diagnosis for PCa is 68 years [13]. There are several available ways to
diagnose localized PCa such as blood PSA levels, digital rectal examination, and Gleason score
of biopsied material. One study suggests that a “Gleason score higher than 6, PSA levels higher
than 40 ng/mL, and white skin color are independent markers of poor prognosis” [14]. There is a
controversy over whether the PSA level should be used for diagnosing PCa, because it often
leads to over detection and patient anxiety from false-positives. However, another study suggests
that having more information is better than having no information at all, and thus, PSA levels
should be used together with other diagnostic techniques to diagnose PCa [15].
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Treatments for Prostate Cancer
Various treatments are available for PCa including active surveillance, radical
prostatectomy, radiation therapy, chemotherapy, and hormonal therapy. The optimal therapy
varies for each person and physicians are encouraged to discuss all available options with the
patient. The available hormonal therapy uses diethylstilbestrol or luteinizing hormone-releasing
hormone to block the cells’ growth response to the AR by reducing the release of testosterone
from the testicles. However, not all PCa cells grow in response to AR so it can lead to selection
of cells that are AR independent [16]. A person can also reduce the risk of PCa by maintaining
their diet and other lifestyle changes. Vitamin A, retinoid, several B vitamins, vitamin C, vitamin
D, and vitamin E act as anti-oxidants to help against PCa [17]. All the available treatments are
only beneficial at early stageS of PCa prior to metastasis. Therefore, there is a high demand for a
treatment that will stop the metastasis and invasion of PCa cells.
The Role of Chronic Inflammation in Prostate Cancer
The role of chronic inflammation in various cancers is well known. Inflammation is the
body’s natural mechanism to fight foreign pathogens, heal damage, and respond to irritants.
Inflammation is usually self-limiting and does not cause any harm to the body; however,
sometimes the control is lost and inflammation becomes chronic leading to various diseases such
as cancer, Crohn’s disease, Blau syndrome, etc. [11]. What sets the fire by initiating
inflammation in the prostate is unknown, but infectious agents increase the risk of PCa [18].
According to Lucia et al, inflammation can cause carcinogenesis by either releasing cytokines or
growth factors that favor tumor growth, inducing the cyclooxygenase-2 enzyme (COX-2), or by
the production of reactive oxygen (ROS) and reactive nitrogen species (RNS). ROS and RNS
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can cause DNA damage and mutagenesis. Macrophages at the inflammatory site also release
other factors that cause angiogenesis and stromal remodeling. The presence of an inflammatory
tumor microenvironment to promote tumor growth was first hypothesized by Virchow in 1863.
Chronic inflammation at the site of the tumor releases various factors that promote the survival
and growth of the tumor. The cells of the immune system include macrophages and leukocytes,
which release a wide spectrum of chemicals such as cytokines, interleukins (IL’s), and growth
factors that mediate inflammation. The receptors for growth factors are found both on the
immune cells as well as on the tumor cells. All of these chemicals together create a tumor
microenvironment and can cause carcinogenesis, tumor growth, and tumor progression [19].
Role of CCR5 and CCL5 in Prostate Cancer
Chemotactic Chemokine Receptor 5 (CCR5) and Chemotactic Chemokine Ligand 5 (CCL5)
play an important role in the immune response and in cancer. CCR5 is a co-receptor for HIV
entry and many anti-HIV drugs are designed as antagonists for CCR5. Chemokines and their
receptors are used by tumor cells to promote angiogenesis, tumor growth, survival and metastasis
[20]. Konig et al. compared the mRNA level of various chemokines and chemokine receptors in
PCa versus BPH and found that CCL5 and CCR5 were both expressed at higher levels in PCa.
Other factors were also up-regulated in PCa such as IL-8, MMP-9, MMP-2, and CXCR-3 [21].
Robinson et al correlated CCR5 and CCL5 with breast cancer disease progression and showed
that a CCR5 antagonist inhibits breast tumor growth in the presence of CCL5 [22]. Vaday et al
used the TAK-779, a receptor antagonist of CCR5 in the presence of CCL5 to test the effect of
the antagonist on prostate cell growth and invasion. They compared the migration index and
growth of DU-145 and PC-3 cells with CCL5 alone or CCL5 plus varying concentrations of
TAK-779. Increasing the concentration of TAK-779 decreased the migration index and reduced
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growth of DU-145 and PC-3 cells indicating that TAK-779 must affect the metastatic ability of
these cells by opposing the effect of CCL5. These results suggest the importance of designing
new, more effective antagonists of CCR5.
The Role of Chemokines in Prostate Cancer
Chemokines and their receptors are used by immune cells such as macrophages and T
cells. Chemokines are small soluble molecules that attract various types of cells such as
leukocytes to induce inflammation. However, since chronic inflammation has been linked to
tumor and cancer, chemokines can also play an important role in creating a microenvironment to
enhance tumor survival. Receptors for chemokines can be found on target cells which by binding
these soluble ligands promote numerous downstream events. Among these chemokines and
chemokine receptors, CCR5 and CCL5 play a vital role in PCa by promoting angiogenesis,
growth, survival, and invasion [20]. Figure 1 diagrams the basic chemokine pathway in cancer
[19].
Tumor Microenvironment
Numerous studies confirm that human and murine tumor cells express chemokines and
chemokine receptors, which are commonly involved in the autocrine pathway supporting the
growth and survival of tumor cells. Figure 1 shows the possible role of macrophages in the tumor
microenvironment in the promotion of tumor growth progression and carcinogenesis. How the
inflammatory response initiates is not known, but once the fire starts, macrophages at the site of
the tumor release various chemokines like mitosis initiation factor (MIF) which promotes cell
division. They also induce the COX-2 enzyme that produces prostaglandins, which promotes
MMP’s, TGF-β, IL-8, and vascular endothelial growth factor (VEGF). Macrophages also release
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Figure 1. Inflammation in Cancer. Macrophages in the tumor microenvironment produce
factors such as MMP, TGF-β, VEGF, RNS, ROS, TNF-α, and interleukins. These factors cause
stromal remodeling and angiogenesis at the tumor site. They also cause mutagenesis of the tumor
epithelial cells and down-regulate apoptotic pathways, leading to mutagenesis. The end result of
stromal remodeling, angiogenesis, and mutagenesis is carcinogenesis and tumor growth
progression. Adopted from Lucia et al [19].
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Figure 1. Inflammation in Cancer.
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TNF-α that binds to its receptor on target cells and causes various downstream events including
both apoptotic death and survival [19]. TNF-α can activate NF-κB and promote cell survival and
proliferation. It can also activate MAPK pathways and caspases to promote apoptosis. IL-8,
VEGF, and TGF-β released from the macrophage promote angiogenesis of tumor tissue to
provide more blood and nutrients to the tumor site. MMP’s cleave extracellular matrix to help
tumor cells metastasize. Macrophages produce ROS and RNS, which cause DNA damage and
inactivation of repair enzymes of tumor cells, causing mutagenesis. Thus, the net effect of the
chemokines is to promote carcinogenesis [19].
Chemokines and Chemokine Receptors
Chemokines and their receptors are grouped into four families. Chemokines are classified on
the position of cysteines within the primary amino acid sequence. In the C family there is only
one cysteine [16]. In CC chemokines the cysteines are adjacent, in CXC and CX3C there is one
or three non-cysteine residues between the cysteines, respectively. Chemokines guide cells as a
chemoattractant by setting up a chemical concentration gradient for chemotaxis (movement of
cells towards a concentration gradient).
Chemokine receptors are also classified in groups based on what chemokines they bind [16].
Chemokine receptors are G-protein-coupled receptors (GPCRs), which can bind many different
ligands. Upon binding of the ligand, chemokine receptors act on G-proteins to activate their
function inside the target cell [16]. Chemokines induce the inflammatory response by attracting
leukocytes to the tumor site and induce tumor growth. According to the counter invasion model,
chemokines are secreted from tumor cells to attract leukocytes, which degrade the extracellular
matrix during entry into the site of tumor, which then allows the tumor cells to enter the blood
vessels and migrate to remote sites [23].

9

Role of MMP in Metastasis of Prostate Cancer
Chemokines play a dual role. Not only do they attract leukocytes and elicit the immune
response to take care of infections or tissue damage, but they also act in tumor survival and
metastasis. There are a few key steps that tumor cells must follow to metastasize, but the exact
mechanism is not clearly defined. In order to metastasize, the tumor cell must detach and
degrade extracellular matrix, enter the blood or lymphatic vessel and then traffic to the remote
tissue [16]. MMP’s are very important in the metastasis process because they are responsible for
degrading the extracellular matrix, specifically the type IV and V collagens. MMP’s are first
secreted as inactive proproteins which are activated by the cleavage of other proteinases. There is
no direct link between MMP-9 level and CCL5 in PCa; however, CCL5 and MMP-9 were both
up-regulated in PCa compared to BPH [21]. Experiments in breast cancer confirmed that CCL5
expression up-regulates MMP-9 and furthers disease progression [16]. Vaday et al. showed that
CCR5 antagonists for CCL5 reduced the invasive and metastatic ability of PCa cells; therefore,
CCL5 must promote metastasis in PCa [20]. This result suggests that CCL5 is involved in the
production of MMP-9, which results in the metastasis of PCa cells.
Chemokines such as CXCL12 and its receptor CXCR4 have been shown to be involved in
breast cancer metastasis. Antibody for the receptor blocked the metastatic ability of the breast
cancer cells [16]. The chemokines possibly setup a chemical gradient to attract cancer cells,
displaying the appropriate receptors. Once these cells have reached the target site, a secondary
tumor develops with the help of similar chemokines found in the tumor environment at the
metastatic site [16].
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CCL5 Function
CCL5 contains 91 amino acids and is part of the CC family of chemokines usually
expressed in T-cells with increased expression following antigen stimulation. CCL5 is one of the
HIV-suppressive factors produced by CD8-positive T cells and is involved in the basic immune
response against viruses. CCR5 is a co-receptor for HIV-entry into cells and CCL5 acts as an
inhibitor of HIV interacting with CCR5. Macrophages use CCL5 to clear viruses and in CCL5deficient mice, viral clearance is delayed [24]. CCL5 exerts its effect by binding to CCR5 on
neighboring cells and activating the ERK, MAPK, and AKT pathways in a paracrine fashion.
CCL5 also binds CCR1 and CCR3 [24]. Previous studies suggest that CCL5 levels are directly
correlated with tumorigenecity and invasiveness of cancer cells [ 20].
CCR5 Structure and Signaling Pathway
CCR5 is a GPCR chemokine receptor belonging to the rhodopsin-like family. It has 7
transmembrane segments (TMS), 3 intracellular loops, 3 extracellular loops, an extracellular Nterminus, an intracellular C-terminus, and is located on chromosome 3p21 in humans [16]. CCR5
is preferentially expressed on Th1 cells, monocytes, macrophages, and immature dendritic cells
[16]. It is also a co-receptor of HIV-1 entry binding to the HIV-1 envelope glycoprotein gp120
along with CD4. A mutation in CCR5 called CCR5∆32 (containing a 32 base pair deletion) leads
to resistance against HIV [16]. CCR5 is “posttranslationally modified by o-linked glycosylation
and sulfation of N-terminal tyrosines” [25]. Rhodopsin-like family members have highly
conserved amino acids and a disulfide bridge that connects the first and second extracellular
loops and many have palmitoylated cysteines in the carboxy-terminal tail. CCR5 has 4 cysteine
residues in its extracellular region and a conserved DRYLA amino acid sequence in the second
intracellular loop to bind G protein (see Figure 2) [16].
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Figure 2. The Two Dimensional Structure of CCR5 with Palmitolyation Sites and Two
Disulfide Bonds.
The 2-D structure of CCR5 is shown with 7 transmembrane α-helical segments with extracellular
N-terminal and intracellular C-terminus. The top side is extracellular whereas the bottom is
intracellular. CCR5 consists of 3 intracellular and 3 extracellular loops. The palmitolyated
cysteines are shown with zig-zag lines. The extracellular cysteines form disulfide bonds depicted
as solid and dashed lines. Adopted from Dr. Yan Zhang’s unpublished grant proposal.
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Figure 2. The Two Dimensional Structure of CCR5 with Palmitolyation Sites and Two
Disulfide Bonds.
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CCR5 binds CCL5 and Macrophage Inflammatory Protein (MIP-α and MIP-β). MIP-α and β
are now known as CCL3 and CCL4 respectively [16, 25]. CCR5 is involved in migration,
chemotaxis, cellular shape changes, metastasis, degranulation, and ROS production [26]. Figure
3 outlines the chemokine/chemokine receptor pathway for CCL5 and CCR5 [27]. CCR5 is
associated with a G-protein and upon ligand binding CCR5 exerts its effect on the cell through
G-protein subunits. G-proteins are trimeric proteins composed of α, β, and γ subunits. Gα
dissociates from Gβγ upon binding GTP and re-associates with Gβγ upon hydrolysis of GTP to
GDP. Ligand binding promotes the exchange of GDP for GTP on Gα and causes the dissociation
of Gα from Gβγ. Subsequently Gβγ binds phospholipase C γ (PLC-γ) which in turn hydrolyzes
phosphatidylinositol-4,5-bisphosphate

(PIP2)

to

inositol-1,4,5-triphosphate

(IP3)

and

diacylglycerol (DAG). PIP2 increases intracellular Ca2+ ion concentration by opening the Ca2+
channel while DAG activates the protein kinase C (PKC) enzyme. Ca2+ forms a complex with
calmodulin and together with PKC activates protein tyrosine kinase 2 (PYK2) through
phosphorylation. PYK2 activates c-Jun N-terminal kinase (JNK) and p38, which then activates cJun and c-Fos respectfully [27]. C-Jun and c-Fos together form the activator protein (AP-1), a
transcription factor, which regulates the gene expression of various molecules such as cytokines
and growth factors. These factors induce chemoattraction, inflammation, tumor growth, and
carcinogenesis [28]. There is no clear evidence linking CCL5 and production of MMP’s but
studies in breast cancer showed that up-regulation of MMP-9 increased with CCL5 expression
allowing the tumor cells to degrade ECM and migrate to the blood vessel [16]. Therefore,
inhibiting CCL5/CCR5 interaction could be an important mechanism to block the production of
proinflammatory signals that sustain chronic inflammation at the tumor site and also promote
tumor growth and metastasis.
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Figure 3. The CCR5 and CCL5 Pathway in Macrophages.
The signaling pathway of CCL5 and CCR5 is depicted. The arrows represent the binding or
activation of each factor in the signal transduction pathway. The blue solid rectangle represents
the plasma membrane, top is extracellular side and bottom is intracellular side. The end result is
the expression of various gene products in the nucleus by the binding of CCL5 to CCR5. Binding
of CCL5 leads to activation of the Gα subunit, which dissociates from Gβ and Gγ. Gα activates
PLCγ, which converts PIP2 to IP3 and DAG. IP3 acts on Ca2+ channel to cause entrance of Ca2+
ions into the cell. DAG activates PKC enzyme. Ca2+ forms a complex with calmodulin (CaM)
and acts on Pyk2 along with PKC to activate Pyk2 through phosphorylation. Pyk2 activates Jnk
and p38, which activates the c-Jun and c-Fos transcription factors in the nucleus. Together they
form the early response transcription factor AP-1. AP-1 leads to the expression of
proinflammatory chemokines [27, 28]. Adopted from Chemokine Signaling pathway at
http://www4.appliedbiosystems.com/tools/pathway/
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Figure 3. The CCR5 and CCL5 Pathway in Macrophages.
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Prostate cancer cell lines
Immortalized prostate cancer cell lines are excellent in vitro models to study PCa. They
allow the study of anti-proliferative, anti-invasive, and anti-metastasis factors [12]. In this
project, three immortalized PCa cell lines have been used to study the effect of CCR5 antagonists
on prostate tumor growth and metastasis. These tumor cell lines do not share any genetic
background and two are derived from metastatic tumor sites.
a. PC-3 Cell line
The PC-3 cell line was isolated from a human PCa metastasis to the lumbar vertebra. PC3 cells are poorly differentiated and do not express PSA. The PC-3 cells are androgen
independent and therefore do not respond to positive estrogen therapy [29]. PC-3 displays
anchorage independent growth and expresses high levels of TGF-α, TGF-β, epidermal growth
factor (EGF), insulin-like growth factor (IGF) and their receptors. These growth factors and their
receptors might form an autocrine loop resulting in autonomous growth for PC-3 cells [30].
b. DU-145 Cell line
The DU-145 cell line was isolated from a metastatic central nervous system (CNS)
tumor. They produce a high amount of TGF-β, EGF, IGF-1, TGF-α and TGF receptor. Like PC3, they also potentially exhibit an autocrine growth loop. DU-145 cells are also androgen
independent and do not respond to positive estrogen therapy [30].
c. M12 Cell line
The M12 cell line was derived from the parental P69SV40T cell line [31, 32]. P69SV40T
was derived by immortalizing cells with a construct expressing the SV40 large-T antigen.
P69SV40T cells were injected subcutaneously into male athymic nude mice where tumors
formed after 9 months. Tumors were retrieved; M1929 cells were isolated and re-reinjected into
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mice for a total of two cycles yielding M2182s and finally the M12 subline. The later subline
was found to be invasive as their orthotropic tumors readily metastasized to the diaphragm and
lungs. Moreover, M12 cells retain their tumorogenecity and metastatic capacity during in vitro
culture as well, as measured by re-injection of cultured M12 cells into male athymic nude mice,
which results in tumor growth requiring euthanasia. After euthanasia, M12 cells were found to
metastasized to lung and diaphragm [31].
Dr. Xueping Zhang’s (Department of Biochemistry, Virginia Commonwealth University,
Richmond, VA) unpublished study compared the level of CCL5 and CCR5 mRNA between P69
and M12 cells by qRT-PCR (see Figure 4). P69 is the non-metastatic and non-tumorigenic
parental cell line for the M12 subline. The M12 subline is highly tumorigenic and metastatic.
The CCL5 mRNA level was highly upregulated in the M12 subline. However, the CCR5 level
was lower in M12 than P69. It was proposed that this lower level of CCR5 was sufficient to bind
enhanced levels of CCL5 and cause the up-regulation of downstream pro-inflammatory
pathways. This result suggested that the level of CCL5 might be directly correlated with the
invasiveness of PCa cells.
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Figure 4. M12 Cells Express More CCL5 mRNA than Parental P69 Cells.
qRT-PCR measured the level of CCL5 and CCR5 mRNA in M12 and its parental P69 cell line.
The bars represent the standard error. P69, the parental cell line of M12, is less tumorogenic than
M12. Adopted from Dr. Xueping Zhang’s unpublished research.
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Figure 4. M12 Cells Express More CCL5 mRNA than Parental P69.
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Anti-Prostate Cancer Drug Design
The interaction between CCL5 and CCR5 was determined to be a good target for the
design of an anti-PCa drug because CCL5 binding to CCR5 promotes the production of
numerous chemokines that induce inflammation, tumor growth, and invasion [27]. Vaday et al
has shown that a known CCR5 antagonist called TAK-779 significantly reduces the growth and
invasiveness of PCa cells in the presence of CCL5 [20]. Based on this result, we hypothesized
that CCR5 antagonists would be effective as an anti-prostate cancer agent. Using molecular
modeling approaches several novel putative CCR5 antagonists were designed by Dr Yan Zhang
(Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA),
which have a high affinity for the CCR5 receptor. The structure of currently known CCR5
ligands including that part which interacts with the CCR5 binding site (the pharmacophore), was
used to design CCR5 antagonists [23]. CCR5 is a GPCR whose crystal structure is unknown.
Due to this fact, homology modeling is commonly used to study GPCR’s. CCR5 belongs to the
rhodopsin family of GPCR’s and the closest GPCR with a known crystal structure is bovine
rhodopsin. Therefore, the bovine rhodopsin crystal structure was used along with the
pharmacophores of the known CCR5 ligands to characterize the binding of CCR5 antagonists.
By this approach, several novel compounds were designed. Energy minimization and molecular
dynamic simulation were used to select the optimal compounds. Based on the binding interface
of the known ligands, Maraviroc and Vicriviroc to CCR5, a molecular scaffold was constructed
[Dr. Yan Zhang’s Unpublished Data].
This scaffold, along with the structure of the ligand binding pocket, was analyzed to
design a basic structure of the novel compounds (drugs) to be tested as CCR5 antagonists [23].
The basic structure of such a drug includes a tri-substituted phenyl ring as a spacer which
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connects amino and amide groups. There is a hydrogen bond acceptor on the phenyl ring.
Different substitutions (R1, R2, and R3) were tried on both ends of the basic molecule.
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II. Thesis Objectives
The purpose of this project was to evaluate the effect of the newly synthesized putative
CCR5 antagonists in the presence of CCL5 on the tumorigenicity and invasiveness of PCa cell
lines. The binding of CCL5 to CCR5 activates downstream signals that promote tumor growth
and invasion. An effective CCR5 antagonist is expected to block this interaction between CCR5
and CCL5, stop the production of those downstream signals, and therefore, inhibit tumor growth
and invasion. Three sets of drugs for a total of 76 drugs were tested for their effectiveness as
CCR5 antagonists on M12, DU145, and PC-3 cell lines. The initial goal was to use a simple
screening assay such as proliferation and cytotoxicity assays to test the effectiveness of all the
drugs. A shortened list of lead drugs would then be subjected to further testing in vitro by a more
rigorous assay such as the invasion assay. The responsibility for the primary assay was divided
between Dr. Xueping Zhang and myself as follows: I would conduct the proliferation and
cytotoxicity assays of the drugs on the M12 cell line whereas Dr. Zhang would conduct similar
assays on the PC3 and DU145 cell lines. I would subsequently test the most effective compounds
from these assays via the invasion assay for M12, PC3, and DU-145 cell lines. The most
effective compounds would then be tested on subcutaneous tumor growth in male, athymic nude
mice in vivo by Dr. Joy Ware (Department of Pathology, Virginia Commonwealth University,
Richmond, VA). The objective was to find the most effective antagonist for CCR5 among the list
of 76 drugs (see Table 1), starting with in vitro assays to assess cell proliferation and invasive
potential and finalizing with in vivo tumor assays.
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Table 1: List of the 76 Drugs That were Tested in in vitro Assays.
Set #

# of Drugs

Drugs

1

24

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22,
23, 24, 25

2

24

27, 29, 30, 35, 36, 37, 38, 39, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63,
64, 65, 66, 67, 68, 69

3

28

21, 26, 28, 31, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 150, 151,
152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162
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III. Materials and Methods

Cell Media
M12 cells were cultured in RPMI 1640 medium (GIBCO Invitrogen, 21870) with 5%
FBS (Invitrogen, S11150), 1% L-glutamine (Invitrogen, 25030), 0.1% ITS (insulin, 5ug/mL;
transferrin, 5ug/mL; and selenium, 5ng/mL), and 0.1% gentamicin 10mg/mL (Gibco 15710).
PC3 and DU145 cells were cultured in RPMI media containing 10% FBS.
2D Cell Culture
PCa cell lines M12, DU145 and PC3 were obtained in frozen aliquots from Dr. Xueping
Zhang. Tubes of the frozen cells were quickly thawed in a water bath at 37°C, resuspended in 10
mL of culture media, centrifuged at 1700RPM for five minutes, and the supernatant removed by
aspiration. The pellet was resuspended in 10mL fresh media and plated on 100mm x 20 mm
plastic tissue culture dishes (Falcon, 353003). The cultures were incubated at 37°C in 5% CO2.
Cultures were split after 80-90% confluency and the media was changed every 48 hours or as
needed.
To split the culture, the old media was first aspirated and 2 mL of trypsin-EDTA (Gibco
Invitrogen, lot #39808) was added to the dish. After a few min when the cells had started to
detach from the plate, 5mL of media was added to loosen the cells and cells plus media were
transferred to a 50 mL centrifuge tube. Following centrifugation at 1700RPM for 5 min, the
supernatant was removed; the cell pellet was resuspended with new media, and plated on a new
dish at a split of 1:4.
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Cell Counting
Cells were removed from the culture by adding trypsin/EDTA and washed with media
containing serum. Cells plus media were transferred to a plastic tube in a total volume of 500uL.
The cells were counted with an automated cell counter called Beckman Coulter (Vi-Cell XR Cell
Viability Analzyer), which differentiates viable cells from dead cells using Trypan blue. If a cell
is viable, it does not absorb trypan blue because of the high selectivity of the plasma membrane
of live cells. However, trypan blue can pass through the membrane of dead cells and therefore it
is absorbed. Thus, dead cells appear blue because of trypan blue absorbance and live cells appear
clear because of the lack of trypan blue absorbance. The cell count was used to determine the
correct number of cells needed for the cell proliferation or invasion assay. Cell counting was also
used in the cytotoxicity assay to determine the number of cells alive after drug addition.
Cell Proliferation Assay
The cell counting method was used to calculate the volume of the media plus cell
solution needed to plate 3000 cells per well in a 96-well plate. The media/cell solution was
diluted with media to a total well volume of 100 uL for each well. To ensure the cells are plated
evenly, 50 uL of media only was first plated and then 50 uL of the properly diluted cell/media
solution was added to each well and gently mixed by pipetting. The plate was placed in the
incubator for 24 hours at 37°C in 5% CO2. After 24 hours, the media was changed and different
drugs were added at varying concentrations to some wells while control wells received only
media. Initially cell growth was measured every 24 hours after drug addition; however, it was
experimentally determined that there was little effect on the growth of these cells before 72
hours. Subsequently, 72 hours became the only time point measured for each drug. After 72
hours, the serum media was aspirated and 100 uL of serum-free media (RPMI 1640 and 0.1%
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gentamicin) was added to each well plus 10 uL of the WST-1 cell proliferation reagent (10% of
the media amount). After 1 hour of incubation, the absorbance of each well was measured using
a Microplate Bio-Kinetics Reader (BIO-TEK instrument) at 450nm, subtracting the background
at 650nm. Each cell line was normalized to its control average. WST-1 is a slightly red solution
which is cleaved to formazan, a dark red product, by the mitrochondrial dehydrogenase enzyme.
The amount of formazan formed is directly related to the activity of the mitochondrial
dehydrogenase, which is correlated to the metabolic rate of active cells in the culture. A higher
absorbance is thought to be proportional to a higher metabolic rate in direct correlation to an
expected higher number of active cells, hence this assay is proposed to measure cell proliferation
(company manual).
Cytotoxicity Assay
A cell count was done to calculate the volume of the cell solution required to plate 20,000
cells per well in a 24 well plate. The cells are diluted with media to a final volume of 1 mL per
well. The plate was then incubated for 24 hours after which the media was changed. Drugs were
added to the experimental wells at 1 uM concentration whereas media only was added to the
control wells. After 72 hours, the cells were washed with 300 uL of PBS per well. To each well,
300 uL of Trypsin/EDTA was added to detach the cells from the plate and 300 uL of media was
added. From this solution, 500 uL was transferred to a plastic tube for cell count. The cell count
for the wells with drugs was compared to the control wells to determine the reduction in cell
growth of cells caused by the addition of drugs. This procedure is referred to as a cytotoxicity
assay since the effect of drug addition of cell growth is directly measured.
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Invasion Assay
The invasiveness of cells was determined by a Transwell filter (Coastar, Cambridge,
MA, USA) assay with an insert of 12.0 µm pore size. Filters were coated with 30 uL of 1:10 icecold Matrigel (BD Biosciences) in media with 10% FBS. Following incubation at 37°C for 30
minutes a thin film of polymerized matrigel coated the filters. Cells were detached from culture
using Cell Stripper (Cellgro, 25-056-CI), washed with serum-free media, and pelleted. The pellet
was resuspended with serum-free media at a concentration of 5x105 cells/mL and 250 uL of this
cell suspension (1.25x105 cells) was added to the top chamber of the well above the matrigelcoated insert. For DU145 and PC-3 cell line, 1.5x105 cells were plated per insert. For drug
testing, the desired concentration of drug was added to the top chamber together with the cells.
To the bottom chamber, 1 mL of 20% FBS media was added containing 20 ng/mL EGF and
5ng/mL of CCL5 as a chemoattractant to enhance cell migration. The inserts containing the M12
cells were incubated for 16 hours, while the inserts containing DU145 and PC3 cells were
incubated for 21 hours before monitoring invasion. The ideal time point and density of cells to
use were determined by repeating the invasion assay at several time points with varying cell
density. Following incubation, both upper and lower chambers were aspirated. Cells were fixed
by the addition of 1 mL of 0.1% glutaraldehyde in PBS to the bottom chamber for 20 minutes at
room temperature. The bottom chamber was aspirated and the filter was stained with 0.1%
crystal violet in PBS for 30 minutes at room temperature. The filter was then rinsed with
deionized water, cut, and placed on a glass microscope slide, with the side facing the bottom of
the chamber down. The non-migratory cells that faced the upper chamber of the filter were
scrapped off using a Q-tip. The filter on the glass slide was mounted using Permount and the
number of migrated cells in 10 random microscopic fields were counted at 40x magnification
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and expressed as a percentage of the control. The results represented the mean ±S.E. of the
percentage of invaded cells relative to the control.
Mathematical Analysis and Statistical Calculation
All results were analyzed via the Microsoft Excel program. Averages were calculated and
the results were plotted as graphs. The standard error was calculated by using the following
equation: Standard error = Standard deviation /√n , where n is the sample size (3 – 7) and
standard deviation was calculated by the excel function.
The Analysis of Variance (ANOVA) between the control wells and wells that received
drug was calculated using the following website which provided the p-value:
http://www.physics.csbsju.edu/stats/anova.html
A p-value of less than 0.05 would indicate that there is 95% certainty that the values between the
control group and the experimental drug group are not equal.
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IV. Results

The Effect of the First Set of Drugs on Cell Proliferation
The effect of the 1st set of 24 drugs on M12 cell proliferation was measured using the
WST-1 reagent as described in “Materials and Methods” [33]. This method measures the
metabolic rate of cells as WST-1 is converted to the product formazan by mitochondrial
dehydrogenase enzymes. The absorbance of formazan was measured on an ELISA plate reader at
450nm, subtracting the background absorbance at 650 nm. An increase in absorbance indicated a
higher metabolic rate, which is proposed to correlate to increased proliferation of cells. An
inhibition greater that 50% was set as the cut-off for a relavent drug effect on cell growth. The
absorbance values of the experimental wells containing various drugs at different concentration
were compared to the control wells without drug. The result was expressed as the relative
percentage of the average of the control wells (Figure 5). Drugs were added at a concentration of
1 µM (red), 100 nM (green), and 10 nM (purple) done in triplicate compared to six control wells
without any drug. The absorbance was measured 72 hours after drug addition. None of the 1st set
of drugs showed a large inhibitory effect (more than 50%) on the proliferation of the M12 cells.
Of all the drugs, drugs 2 and 4 showed some inhibitory effect that correlated with the drug dose
being tested, i.e., inhibition was greater at 1μM than at 10nM. Drug 6 displayed growth
inhibition but with little correlation to drug concentration. Several drugs (7, 10, 12, 19, 25)
showed partial inhibition of growth, which was in opposition to drug dose, i.e., inhibition was
greater at lower concentrations than higher.
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Figure 5. First Set of Drugs Showed No Inhibitory Effect on Growth of M12 Cells.
The effect of the first set of 24 drugs at concentrations of 1 μM, 100 nM, and 10 nM were
measured on cell proliferation. Proliferation was monitored after 72 hours of drug addition by
measuring WST-1 absorbance at 450 nm. There were six controls per microplate and four
microplates were used for the assay. The bars represent the standard error.
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Figure 5. First Set of Drugs Showed No Inhibitory Effect on Growth of M12 Cells.
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To refine technical expertise, the proliferation assay for these first set of drugs was
repeated as above with five control wells minus drug (Figure 6). A few members of the
experimental groups (drugs 2, 6, and 10) were specifically highlighted (on the far right of Figure
6) to see if their effect in trial one was replicated it trial two. The result was very similar to the
first trial. None of these drugs showed a large inhibitory effect, including the selected drugs 2, 6,
and 10. Concurrently, Dr. Xueping Zhang conducted the proliferation assay of the same drugs at
similar concentrations on DU-145 and PC-3 cells in triplicate with six control wells minus any
drug. Unpublished data showed similar results as Figure 5 and 6: most of the first set of these
drugs showed little inhibitory effect on the proliferation of the DU145 or PC-3 cells, with the
exception of drug 17, 18, and 22.
To further verify these results, Dr. Xueping Zhang repeated the proliferation assay on a
selected group of drugs which had shown some inhibitory effect (drugs 2, 6, and 10) on the
previous proliferation assays and some that did not have any effect (drugs 17, 18, 22) at the same
drug concentrations on M12, DU145 and PC-3 cells. Her unpublished data (see Figure 7)
confirmed that none of these drugs inhibited the proliferation of M12 cells, but drugs 17 and 22
did significantly inhibit the proliferation of DU-145 cells (p-values < 0.05) at 1 µM
concentration (see Table 2). Furthermore, drugs 17 and 22 also significantly inhibited the
proliferation of PC-3 cells at 1 µM and 100 nM concentrations (p-values < 0.05). Drug 17
displayed the highest amount of inhibition (> 96% inhibition) for both DU145 and PC-3 cells.

The Effect of the Second Set of Drugs on Cell Proliferation
Dr. Xueping Zhang carried out the proliferation assay in triplicate on the 2nd set of 24
drugs at 1 μM concentration on DU145 and PC-3 cells as above. Four control wells were used
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Figure 6. Repeated Proliferation Assay Showed No Inhibitory Dffect for the First Set of
Drugs.
The repeated cell proliferation assay in triplicate of the 1st set of drugs on M12 cells observed
after 72 hours of drug addition at concentrations of 1 µM, 100 nM, and 10 nM. Four microplates
were used and each plate contained five control wells without any drug. Drug 2, 6, and 10 were
highlighted to observe the reproducibility of the first proliferation assay. The bars represent the
standard error.
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Figure 6. Repeated Proliferation Assay Showed No Inhibitory Effect for the First Set of
Drugs.
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Figure 7. Drug 17 and Drug 22 Inhibit Proliferation of DU145 and PC3 Cells.
The proliferation of M12, DU145, and PC3 cells was observed after 72 hours of drug addition
monitoring WST-1 absorbance at 450nm. Growth is expressed as the relative absorbance
compared to the average of the control wells lacking drug. The drug concentrations of 1 µM, 100
nM, and 10 nM were tested in triplicate with six control wells for each cell type. The bars
represent the standard error. Drugs 17 and 22 showed significant inhibition of growth.
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Figure 7. Drug 17 and Drug 22 Inhibit Proliferation of DU145 and PC3 Cells.
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Table 2: Inhibitory Data of Drugs 17 and 22.
The inhibitory data for Drugs 17 and 22 is shown with their p-values from the ANOVA test. The
gray boxes indicate that the particular drug caused no significant inhibition on the cells at that
particular concentration.
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Table 2: Inhibitory Data of Drugs 17 and 22.
Drug ID

Conc

DU145 inhib.

p-value

PC3 inhib.

p-value

17

1uM

97%±0%

0.0001

96%±0%

0.0001

17

100nM

96%±0%

0.017

22

1uM

64%±1%

0.0001

22

100nM

64%±1%

0.0001

90%±4%

0.0001
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for each cell type. Unpublished data indicated no inhibitory effect by any of the drugs from the
2nd set; thus, the effect of this drug set on the M12 subline was not further tested.

The Effect of the Third Set of Drugs on Cell Proliferation
Dr. Xueping Zhang tested the effect of the 3rd set of 28 drugs on the cell proliferation of
DU145 and PC-3 cells as above using three control wells for each cell type. Her unpublished
data showed a moderate inhibitory effect on the proliferation of DU145 and PC-3 cells by drugs
46, 48, 50, 151, 157, and 160. Due to the promising results, I carried out the proliferation assay
on the 3rd set of drugs at an 1 μM concentration in triplicate on M12 cells. Each microplate
contained six control wells. The relative absorbance values indicated a moderate inhibition of
proliferation by a few of the same drugs that showed an inhibitory effect on DU145 and PC-3
cells (Drugs 46, 48, 50, 151, 157, and 160) (see Figure 8). However, none showed inhibition
greater than 50%, our designated cut-off for relevant inhibition.
Since the same drugs showed some effect on growth, the proliferation assay was
selectively repeated by Dr. Xueping Zhang on all three cell lines as above. Thus the effect of
these drugs at a 1 µM, 100 nM, and 10 nM concentration was assessed in triplicate on M12,
DU145, and PC-3 cells (Figure 9). However, upon repeat none of the 3rd set of drugs displayed a
large inhibitory effect on the proliferation of any of these cell lines.

The Effect of the First set of 24 drugs on Cytotoxicity
After testing the effect of all the drugs on cell proliferation only a few drugs from the 1 st drug set
were found to have a significant inhibitory effect (>50%) on the growth of the three
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Figure 8. A Few Drugs from the Third Set of 28 Drugs Moderately Inhibit M12 Cell
Proliferation. The proliferation assays of the 3rd set of drugs using WST-1 reagent. Drugs 46,
48, 50, 151, 157, and 160, which had showed a moderate inhibitory effect on PC3 and DU145
cells were highlighted here to see if the effect was repeated for M12 cells. The result is expressed
as the relative absorbance of the experimental wells compared to the average of the control wells.
The bars represent the standard error.
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Figure 8. A Few Drugs from the Third Set of 28 Drugs Moderately Inhibit M12 Cell
Proliferation.
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Figure 9. Selected Third Set of Drugs Showed No Inhibition of M12, DU145, or PC-3 Cell
Proliferation. Six drugs that showed a moderate inhibitory effect on DU145, PC3, and M12
cells in previous proliferation assays were repeated in triplicate for all three cell lines at a 1 µM,
100 nm, and 10 nm concentration by Dr. Xueping Zhang. WST-1 reagent was used for the assay,
whose absorbance was measured at 450nm. The result is expressed as the relative absorbance of
the experimental wells compared to the average absorbance of the control wells without any
drug. The bars represent the standard error.
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Figure 9. Selected Third Set of Drugs Showed No Inhibition of M12, DU145, or PC-3 Cell
Proliferation
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prostate cancer cell lines. Based on the results from repeated, similar proliferation assays, the 2nd
and 3rd drug set were ruled out and only the 1st drug set revealed any drugs worth further testing.
It was proposed that the effect of these drugs on cell proliferation was worth analyzing by
a second approach. The WST-1 reagent measures metabolic activity. A more direct measurement
of growth would be to directly count the number of live versus dead cells. Thus, a cytotoxic
assay was developed. This assay involves the direct counting of viable cells 72 hours after the
addition of the drugs using trypan blue staining to distinguish dead cells from live cells. The
cytotoxic effect of drugs from the 1st set was first tested on M12 cells, plating 20,000 cells per
well. For the experimental wells a drug concentration of 1 μM was used in triplicate, whereas 3
control wells received no drug. The result was expressed as the relative percentage of viable cells
compared to the average of the control wells without any drug (see Figure 10). Several drugs
showed inhibition of growth of M12 cells. Some drugs displayed high inhibitory effect while
some did not. Drugs 1,2,6,7,8,9,13,15,16,20,22,24 showed more than 50% growth inhibition
with p-values <0.05. To test the effect of these drugs on other cell types (DU145 and PC3 cells),
the cytotoxicity assay was carried out by Dr. Xueping Zhang using a drug concentration of 1 μM
on 60,000 cells per well with 3 control wells (no drug). Her unpublished data (see Figure 11)
showed that drug 17 yielded the highest percent of growth inhibition on both DU145 and PC-3
cells (31% and 41% respectively). Other drugs such as drug 3 yielded some inhibition for one
cell type which was not confirmed in other prostate cell lines.
Hence drugs that showed marginal inhibition in only one cell line were not pursued at
this time. Based on all these results, drug 17 was chosen to be the lead compound for further
testing.
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Figure 10. The Cytotoxicity Assay of the First Set of 24 Drugs on M12 cells.
The cytotoxic effect of the 1st set of drugs (1 μM concentration) was measured on M12 cells
(20,000 cells/well). The viable cells count was determined 72 hours after drug addition. The
result was expressed as the relative number of live cells in the experimental wells compared to
the average of the control wells that received no drug. The bars represent the standard error.
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Figure 10. The Cytotoxicity Assay of the First Set of 24 Drugs on M12 Cells.
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Figure 11. Drug 17 Caused the Highest Inhibition of DU145 and PC-3 Cells via the
Cytotoxicity Assay. The cytotocity assay for the first set of drugs (at 1 μM) on the DU145
(white bars) and PC-3 cells (red bars). The number of live cells was counted for each well, 72
hours after drug addition. The result was expressed as the relative cell count of the experimental
wells compared to the average of the control wells. The data for drug 17 is recorded as blue
(PC3) and white (DU145) since drug 17 yielded the greatest inhibition for both cell lines.
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Figure 11. Drug 17 Caused the Highest Inhibition of DU145 and PC-3 Cells via the
Cytotoxicity Assay
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The Effect of Drug 17 on Proliferation
After selecting drug 17 as the lead compound, additional proliferation assays were done
in triplicate for M12, DU145, and PC-3 cells using a 10 µM drug concentration. The choice of a
higher concentration was based on the fact that the lower concentration showed little inhibition
in previous proliferation assays and perhaps a higher concentration was needed to inhibit growth
of M12 cells. Drug 17 at a 10 µM concentration significantly inhibited the proliferation of all
three cell types (see Figure 12). Inhibition was the greatest for PC3 and DU145 at 94% and 90%
respectively, but still, very significant for M12 cells at 71%, all with p-values equal to 0.0001.
The proliferation assay was repeated in triplicate for drug 17 on just M12 cells using a
broader range of drug concentrations (10 µM, 1 µM, 100 nM, 10 nM, and 1 nM). Drug 17
significantly inhibited the proliferation of M12 cells at a concentration of 1 µM and 10 µM (see
Figure 13). The level of inhibition was similar for both drug concentrations (78%±1% and
77%±2%, and p-values = 0.0001 for both concentrations). To find the half-maximal inhibitory
concentration (IC50) for drug 17 on M12 cells, the data was transformed into log scale of base
10 (see Figure 14). The log growth% and log concentration was plotted using Excel Curve
Fitting software (see Figure 14). From this plot the IC50 was found to be 237.68 nM. To
determine the IC50, the log of 50% was taken, which was equal to -0.301. The x-value for this yvalue was found on Figure 14 to be 2.376. The inverse log of this value indicated that the
concentration of drug 17 which yielded 50% inhibition of growth was 237.68 nM.
The Effect of Drug 17 on the Cytotoxicty of PCa Cells
The cytotoxicity assay was repeated on M12, DU145, and PC-3 cells for only drug 17 to
determine if similar inhibitory results were as reproducible as the results from the proliferation
assays (Figures 13 and 14). Drug 17 (at 1 μM) was analyzed in triplicate with 3 control wells for

50

Figure 12. Drug 17 Inhibited Proliferation of DU145, PC3, and M12 cells at 10 µM
Concentration.
The proliferation assay of DU145, PC3 and M12 cells observed after 72 hours by measuring
WST-1 absorbance at 450nM. Each cell type received drug 17 at 10 µM. The assay was done in
triplicate with six control wells minus drug. The growth was expressed as the percentage of the
control, with bars representing the standard error and p-values = 0.0001.
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Figure 12. Drug 17 Inhibited Proliferation of DU145, PC3, and M12 Cells at 10 µM
Concentration.

Cell Type
DU145
PC-3
M12

Inhibition by 10uM drug 17
90% ± 0%
94% ± 0%
71% ± 0%
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p-value
0.0001
0.0001
0.0001

Figure 13. Drug 17 Significantly Inhibited M12 Proliferation at 1 uM.
The proliferation assay of M12 cells observed after 72 hours of drug 17 addition at
concentrations of 10 µM, 1 µM, 100 nM, 10 nM and 1 nM by the measurement of WST-1 at
450nm. Each drug concentration was repeated in several wells with eight control wells. The bars
represent the standard error.
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Figure 13. Drug 17 Significantly Inhibited M12 Proliferation at 1 uM.

Drug 17 concentration
1µM
10µM

%inhibition
78%±1%
77%±2%
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p-value
0.0001
0.0001

Figure 14. Calculation of the IC50 for Drug 17 Inhibition of M12 Cell Proliferation.
The data from Figure 13 was transformed into log values by taking the log based 10 of the
percentage growth and concentration and plotting the data in loggrowth% vs logconcentration plot. The
linear spline fit model was used on the Excel Curve Fitting software to fit the data. The
intersection of the red lines indicate the coordinate where loggrowth%=-0.301 or percentage growth
= 50%. The y-value of the coordiate (2.376) indicates the logconcentration where percentage growth
is 50%. Taking the inverse log shows the concentration = 237.68 nM, which is therefore the
IC50.
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Figure 14. Calculation of the IC50 for Drug 17 Inhibition of M12 Cell Proliferation.
loggrowth%

vs logconc

with linear spline fit

-0.05
-0.15

x= -0.301, y = 2.376

loggrowth%
-0.25
-0.35
-0.45
-0.55
-0.65
0

1.2

2.4
logconc
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3.6

each cell type. Drug 17 significantly inhibited the growth of all three cells types in the
cytotoxicity assay (see Figure 15). Interestingly, the greatest inhibition of 97% was observed for
the M12 cell line, but significant inhibition of 75% and 70% was observed for DU145 and PC3
respectively. It was evident that drug 17’s inihibitory effect was repeated both in the cytotoxicity
and proliferation assays, indicating drug 17 might be an important CCR5 antagonist to reduce the
growth and proliferation of PCa cell lines.
The Effect of Drug 17 on in vitro Invasion
To date only the growth and proliferation of the PCa cells was assessed by the
cytotoxicity and proliferation assays. The effect of drug 17 on invasion in vitro was next
investigated. Since the invasion assay is considerably more expensive and time consuming, it is
not an efficient way to screen a large number of drugs. Therefore, only the lead compound, drug
17, was assessed for its effect on cell invasion. By this method cells were plated on top of a gel
of extracellular matrix components (transwell filters) and the ability of the cell to degrade the
matrix components and move from the top to bottom chamber was measured as an index of the
cell’s invasive capabilities. For each cell type drug 17 was added to the experimental insert (at 1
µM concentration), whereas the control insert received no drug. Due to the higher motility of
M12 cells, these cells were allowed to invade for 16 hours, whereas 21 hours was found to be
optimal for DU145 and PC-3 cells. Following invasion, cells were counted under the microscope
and the number of cells that migrated to the bottom chamber were recorded (Figure 15).
Drug 17 significantly reduced the invasiveness of all three PCa cell lines, with the effect
on M12 cells being the greatest at 75%, followed by PC-3 cells at 49% and DU145 cells at 41%
(see Figure 15). Overall, the invasion of all cell types was greatly reduced by drug 17, indicating
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Figure 15. Drug 17 Significantly Inhibits Growth in a Cytotoxicity Assay.
The number of viable M12, DU145, and PC-3 cells were counted after 72 hours of drug 17
addition at 1 µM. Proliferation is expressed as a relative % of the control without drugs. Each
concentration was repeated in triplicate for each cell type and there were three control wells. The
bars represent the standard error. The result was summarized below the figure.
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Figure 15. Drug 17 Significantly Inhibits Growth in a Cytotoxicity Assay

Cell type
M12
DU145
PC3

Inhibition by 1µM Drug 17
97%±2%
75%±9%
70%±6%
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P-value
0.0004
0.0025
0.0008

that it not only inhibits the growth and proliferation of PCa cells, but also reduced their invasive
ability. Since the inhibitory effect of drug 17 was reproduced for all three cell types in multiple
in vitro assays, drug 17 may be an effective CCR5 antagonist. However, the effect of drug 17
remained to be tested in vivo.

The Effect of Drug 17 on in vivo Tumor Growth
Dr. Joy Ware and Ms. Amanda Richardson (Department of Pathology, Virginia
Commonwealth University, Richmond, VA) were responsible for testing the effect of drug 17
on tumor growth in vivo. M12 cells were subcutaenously injected into a group of male, athymic
nude mice and tumors were allowed to form. Tumor growth was measured by a caliper where
approximate tumor volume (mm3) was calculated as: (length x width2) /2. Once tumors reached
a predetermined optimal size of at least 50 mm3, mice were deemed ready for injection. Four
experimental mice and three control mice were used. Both groups of mice were injected at 4 day
intervals for a total of 4 injections. Tumor growth was monitored upto 8 days post the last
injection. Control mice received no drug, only the carrier ddH2O and 10% DMSO, while the
experimental mice received 1 μM drug 17 resuspended in ddH2O and 10% DMSO each. The
unpublished data of Ware et al showed that the tumor volume was less for mice that received
drug 17 compared to the control mice that did not receive any drug (see Figure 16). Comparing
the average tumor size of the control and experimental groups indicated a significant difference
in the tumor size between the two groups on the 3rd and 4th injection days (46% and 64%
respectively, with p-values 0.0036 and 0.0052 respectively) (see Table 3). Each mouse started on
the 1st injection day with a slightly different tumor size; the control group actually had smaller
tumors at the beginning of the study. Over time, a difference in the tumor size started to emerge
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Figure 16. Drug 17 Significantly Reduced Invasiveness of DU145, PC3 and M12 Cells.
DU145, PC3 and M12 cells were plated on top of Matrigel coated transwell inserts as mentioned
in “Material and Methods”. Cells were counted from 10 random fields at 40x magnification and
results were expressed as the relative average cell count compared to the control insert without
any drug. Drug 17 was added at 1 µM. The bars represent the standard error. The result was
summarized below the figure.
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Figure 16. Drug 17 Significantly Reduced Invasiveness of DU145, PC3 and M12 Cells.

Cell type

Inhibition of invasiveness by 1µM drug 17

p-value

DU145
PC3
M12

41%±3%
49%±4%
75%±2%

0.0012
0.0001
0.0001
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Figure 17. Drug 17 reduces tumor growth in vivo.
M12 cells were injected subcutaneously into nude mice by Ware et al and tumors were allowed
to form. Control mice received only ddH2O and 10% DMSO at each injection, while the
experimental mice received drug 17 at a 1 µM concentration resuspended in ddH2O and 10%
DMSO. The drug was injected four times at four day intervals. Tumor volume was calculated
prior to each injection. Mice were monitored upto 8 days post last injection except for mouse 9
which abrutly died after the 4th injection. In the graph, the doubled lines are control mice and the
single lines are experimental mice.
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Figure 17. Drug 17 reduces tumor growth in vivo.
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Table 3. Tumor Volume and Percent Inhibition of Tumor Size by Drug 17.
(A)The tumor volume at each day of injection, plus 4 and 8 days post last injection is listed for
each mouse. (B) The percent inhibition in tumor volume caused by drug 17 was calculated by
finding the percent difference between the average tumor sizes of control mice and experimental
mice and dividing by the average tumor size of the control mice. P-values calculated between the
two groups is listed. Unpublished data by Ware et al.
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Table 3. Tumor volume and Percent Inhibition of Tumor Size by Drug 17.
A
4 days post 8
days
inj.
post inj.

Mouse id

1st inj

2nd inj

3rd inj

4th inj

mouse 9 c17

56.7

44.1

60.0

66.3

mouse 15 c17

63.5

52.3

60.0

89.2

87.9

137.30

mouse 8 c17

46.4

48.4

33.6

32

37

67.5

mouse 6 c17

42.4

41.6

40.0

40

47.1

69.3

mouse 3 control

48.4

70.2

88.9

154.6

147.5

164.7

mouse 10 control 37.6

51.6

92.5

129.6

135

167.9

mouse 1 control

37.0

45.6

89.2

191.1

456.3

505.4

mouse group

1st inj

2nd inj

3rd inj

4th inj

4days post

8 days post

Experimental avg

52.3

46.6

48.4

56.9

57.3

91.4

Control avg
% inhibition

41.0
-27%

55.8
16%

90.2
46%

158.4
64%

246.3
77%

279.3
67%

p-value

0.14

0.23

0.0036

0.0052

0.15

0.18

B
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where by the 2nd injection day, drug 17 caused a 16% reduction in tumor volume in the
experimental group. The reduction in tumor volume increased on the 3 rd injection day to 46%
and by the 4th injection day was 64%. The highest reduction was achieved 4 days after the last
injection (77%), which was reduced to 67% by 8 days.
Investigating the average tumor volume for each group in Table 2, it is evident that the
tumor volume stayed almost constant for the experimental group that received drug 17. The
average volume at the start is 52.3 mm3 and reached only 57.3 by 4 days after the last injection.
However, for the control group, the tumor grew large, starting at 41.0 mm3 on the first injection
day, and reaching 246.3 mm3 by day 4 after the last injection. Perhaps for the experimental group
the tumor size did not increase because drug 17 inhibited tumor growth, but the tumor grew
uncontrollably in the control group without drug 17. However, by 8 days after the last injection,
the tumor size started to increase for the experimental group, reaching 91.4 mm3, perhaps
because drug 17 was no longer being injected into the mice and the residual amount of drug 17
was being cleared from the body. The tumor also continued to grow for the control mice,
reaching 279.3 mm3 by day 8 post injection. For the experimental group, once the injection of
drug 17 was stopped, the inhibitory effect started to decrease (from 77% on 4 days post 4 th
injection, to 67% by 8 days post 4th injection). This suggested that the presence of drug 17 could
stop the growth of the subcutaneous tumor in male nude athymic mice.
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V. Discussion

In the discovery of a potent CCR5 antagonist that could function as a potent anti-prostate
cancer drug, many in vitro assays were employed to screen 76 newly synthesized putative CCR5
antagonists. The journey started with a proliferation assay that after several trials suggested that
drug 17 significantly inhibited the proliferation of M12, DU145, and PC-3 cells. This result was
confirmed by a cytotoxicity assay. Since drug 17 was the only drug that showed a reproducible
inhibitory effect by both assays, it was chosen as the lead compound for further studies. The
computation of a full drug response curve yielded an IC50 of 237.68 nM for drug 17 on M12
cells. The cytotoxicity assay for drug 17 was repeated yet again to re-confirm its inhibitory effect
on all 3 PCa cell lines. In all cases the results from the cytotoxicity and proliferation assays
agreed. Finally, an in vitro invasion assay confirmed drug 17’s ability to block PCa cells from
degrading and moving through the extracellular matrix to a bottom chamber in a transwell assay
system. This result strenghtened drug 17’s candidacy as a good CCR5 antagonist with suitable
anti-PCa properties, because not only did it inhibit the growth of PCa cells, but it also inhibited
invasion. However, this was all in vitro findings and the story could be totally different in vivo.
Therefore, the only way to truly validate drug 17’s efficacy was to do an in vivo assay.
Therefore, Ware et al subcutaneously injected M12 cells in two groups of mice. After tumor
formation, one group received injection of drug 17 (1 μM) whereas the other group received only
the carrier. Their unpublished data showed that drug 17 stopped the growth of the tumor, but
once injections were stopped this effect diminished over time probably due to the clearance of
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the drug by the body. However, only a few mice were available for this study. An additional
study with more mice needs to be done to obtain statistically significant results.
The first few attempts to investigate the effect of the novel CCR5 antagonist in proliferation
assays produced no large inhibitory effect by any of the drugs. A few drugs showed small
inhibition, but their results were not reproducible. The standard error for these first few assays
was very high, because I was still perfecting the technical component of these assays.
Concurrently, Dr. Xueping Zhang carried out proliferation assays on DU145 and PC3 cells and
concluded that few of the drugs had any substantial effect on proliferation. She selected a few
drugs that showed a small amount of inhibition or no inhibition and repeated the prolfieration
assay. This time drug 17 showed a significant inhibition of cell proliferation for DU145 and PC3 cells. Drug 18 and 22 also showed some inhibitory effect, but drug 17’s effect was much
greater. She then tested the 2nd drug set on proliferation of M12 and PC3 cells and found none of
the drugs inhibited proliferation. I decided to not focus on this drug set, since she did not see any
effect. She went on to test the 3rd set of drugs on DU145 and PC-3 cells, and I tested M12 cells.
Only a few drugs showed a small amount of inhibition at 1 µM concentration. However, upon
repetition, no significant inhibition was observed by any of these drugs.
At this point we were left with only the first set of drugs to be re-tested, because sets 2
and 3 did not produce any promising results. We decided to try a new method to test the effect of
drugs on tumor cell growth. The former proliferation assay measures the converstion of the
WST-1 reagent to formazan by mitochondrial dehydrogenase enzyme. Thus, this proliferation
assay does not really count the number of viable cells, but relies on mitochondrial activity as an
approximation of cell growth. If more metabolically active cells are present, more formazan
product will be produced. This may or may not reflect a change in cell number and viability.
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There are many factors that can effect the result of this assay, such as whether all the cells absorb
the WST-1 reagent equally, how well it reacts with the mitochondrial dehydrogenase enzyme,
whether more formazan product directy correlates to the number of cells or if larger cells with a
higher number of active mitochondria can produce more formazan than others, etc. Thus, we
wanted to develop an assay that could directly quantitate how many cells are killed by these
drugs compared to the control. The cytotoxicity assay was developed to address this question. It
does not use any enzymatic reaction to measure the number of cells, but rather direct counting of
the number of viable versus stained dead cells in each well by the use of a microscope. It is
therefore a more accurate measure of how many cells survive in the control versus the
experimental wells dependent upon drug addition.
Another factor that reduced the accuracy of the proliferation assay was the fact that
plating the cells in the small well of the 96-well micro plate is very difficult. It is near impossible
to plate the cells evenly in such a small well. If the cells are not evenly plated then the results are
not accurate. The technique was somewhat improved by first adding a small volume of media to
the well followed by the addition of cells resuspended in media. By this approach the cells would
not bounce off the plastic, but rather have a solvent to land on and spread out evenly. It was a lot
easier to plate cells for the cytotoxicity assay because we used a 24 well plate where the volume
was much greater. In this case, the cells were more evenly distributed in the wells. This increased
the accuracy of the results for the cytotoxicity assay compared to the proliferation assay.
However, it is important to note that the first implication of drug 17 as a possible lead compound
actually came from the result of the proliferation assay of the selected 1st drug set done by Dr.
Xueping Zhang. Why drug 17 did not show up on my assay is something worth considering?
This may be due to my previous inexperience. I started the project with no previous experience
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of cell culturing or any of the assays that were used for this project. It has been a learning curve
throughtout the entire project. Due to Dr. Xueping Zhang’s years of experience with these
methods, her results were more accurate from the start. Since I was still learning, my
proliferation assays for the first set of drugs did not show any inhibitory effect by drug 17.
Interestingly, Dr. Zhang’s first assay also did not show any inhibition by any drug. However,
when she repeated the assay the second time for a few selected drugs, the inhibitory effect for
drug 17 became evident. Since she was more experienced with the assays, she tested the 2nd drug
set first and concluded no drugs were effective. Based on her data, I decided to not spend time to
test the second drug set on the M12 cell line. Dr. Zhang showed some drugs within set 3 had a
marginal effect on DU145 and PC-3 cells. I confirmed a small amount of growth inhibition in
my analysis of the M12 cells. However, when Dr. Zhang repeated the assay of these selected
drugs on all three cell types, none of the drugs produced a large enough inhibitory effect to be
considered lead compounds.
In my first try of the cytotoxicity assay on the M12 cells. I found several drugs from set 1
that inhibited cell growth, including drug 17 to a small extent. However, Dr. Zhang’s
cytotoxicity assay of the 1st drug set on DU145 and PC-3 cells confirmed only drug 17 to be
effective in all 3 cell types. Analyzing all other data it was decided to focus only on drug 17,
because its inhibitory effect was evident on both the cytotoxicity and the proliferation assays.
The proliferation assay for drug 17 was repeated with a higher concentration on all three cell
types because I did not see a significant effect by drug 17 in the previous assays with lower
concentrations. Drug 17 at a 10 µM concentration significantly inhibited the growth of all three
cell lines in the proliferation assay. Assaying different drug concentrations on M12 showed that
drug 17 significantly reduced the proliferation of M12 cells at 1 µM and 10 µM concentrations.
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This is the first time drug 17’s inhibitory effect was noted at the 1µM level. One reason might be
due to my mastering a new technique. After several repeats; however, my results started to agree
with the findings of Dr. Zhang. Subsequent cytotoxicity assays confirmed that drug 17
significantly inhibited the proliferation at 1µM concentration for all three cell types, increasing
the confidence of these results.
A protocol for the invasion assay had not been developed in the lab necessiating several
tries (at least 5) to deduce the correct number of cells and time to promote cell invasion.
However, this careful study actually helped alleviate some of my problems encourntered with the
proliferation and cytotoxicity assays. The invasion assay is a better technique to measure the
carcinogenic potential of PCa cells, because it measures the metastatic ability of the cells. Other
assays measure the growth rate of the cells, which may be similar for tumor and normal cells.
Many tumor cells are anti-apoptotic so they can outgrow the normal cells. A faster growth might
not always indicate carcinogenicity. However, normal cells are not invasive and therefore, the
invasion assay is a more accurate way to assess cell carcinogeneicity. The in vitro invasion assay
indicated a significant inhibition by drug 17 on the invasion of all three cell types. Altogether
three completely different assay methods agreed that drug 17 is a potential CCR5 antagonist that
reduced the growth and invasion of the PCa cells in vitro. More importantly, these results were
confirmed in vivo by Dr. Joy Ware where the administration of drug 17 significantly slowed
subcutaneous tumor growth. Once drug 17 administration was stopped, by day 8 tumor growth
began to resume. However, these preliminary results need to be repeated before reaching the
conclusion that compound 17 is a worthwhile drug of possible therapeutic value.
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VI. Conclusion

PCa is a major problem for men of age 50 years or older. Current treatments are only
effective at an early stage and once cancer cells progress to becoming metastatic, palliative care
is the only option. The metastasis of prostate cancer cells to bone is fatal and demands a therapy
that stops invasion and metastatic spread. CCL5 and CCR5 were found to be important in PCa
cells. Previous studies have shown that CCL5 levels are directly correlated with high growth rate
and invasiveness of PCa cells. CCL5 interacts with CCR5 to produce downstream
proinflammatory factors that support the growth and invasion of PCa cells; therefore the
interaction of CCL5 with CCR5 is an important therapeutic target for PCa [19]. Here, several
novel putative CCR5 antagonists were designed based on the known ligand structures for CCR5.
Their inhibitory effect was tested on M12, DU145, and PC-3 PCa cell lines by several in vitro
assays measuring cell growth and invasion. Altogether these studies suggested drug 17 as a lead
compound to significantly inhibit the growth and proliferation of PCa cells. The result was
substantiated in in vivo studies in male, athymic nude mice. In vivo data confirmed that drug 17’s
inhibitory effect was not just evident in vitro, but also in in vivo. Based on several in vitro assays
and in vivo confirmation, it can be concluded that drug 17 might be an important CCR5
antagonist, which has a strong potential as an effective therapeutic agent for PCa.
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